CA2797098C - Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof - Google Patents

Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof Download PDF

Info

Publication number
CA2797098C
CA2797098C CA2797098A CA2797098A CA2797098C CA 2797098 C CA2797098 C CA 2797098C CA 2797098 A CA2797098 A CA 2797098A CA 2797098 A CA2797098 A CA 2797098A CA 2797098 C CA2797098 C CA 2797098C
Authority
CA
Canada
Prior art keywords
dosage form
active agent
biologically active
form according
liquid biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2797098A
Other languages
English (en)
French (fr)
Other versions
CA2797098A1 (en
Inventor
Francois Ravenelle
Dorothee Le Garrec
David Lessard
Sandra Gori
Damon Smith
Miloud Rahmouni
Vinayak Sant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paladin Labs Inc
Endo Ventures Ltd
Original Assignee
Paladin Labs Barbados Inc
Paladin Labs Inc
Paladin Labs Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paladin Labs Barbados Inc, Paladin Labs Inc, Paladin Labs Europe Ltd filed Critical Paladin Labs Barbados Inc
Publication of CA2797098A1 publication Critical patent/CA2797098A1/en
Application granted granted Critical
Publication of CA2797098C publication Critical patent/CA2797098C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2797098A 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof Active CA2797098C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32734810P 2010-04-23 2010-04-23
US61/327,348 2010-04-23
PCT/CA2011/000447 WO2011130834A1 (en) 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Publications (2)

Publication Number Publication Date
CA2797098A1 CA2797098A1 (en) 2011-10-27
CA2797098C true CA2797098C (en) 2019-03-26

Family

ID=44833585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797098A Active CA2797098C (en) 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Country Status (6)

Country Link
US (1) US20130039864A1 (https=)
EP (1) EP2563349A4 (https=)
JP (2) JP2013530931A (https=)
CA (1) CA2797098C (https=)
IL (1) IL222568A (https=)
WO (1) WO2011130834A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
GB2561009B (en) * 2017-03-31 2020-05-13 Altus Formulation Inc Non-ionic PVP-PLA block copolymers and pharmaceutical compositions derived therefrom
WO2021247463A1 (en) * 2020-06-02 2021-12-09 Purdue Research Foundation Formulation of monodisperse kinetically frozen polymer micelles via equilibration-nanoprecipitation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
MXPA05004410A (es) * 2002-10-25 2005-11-23 Labopharm Inc Composiciones de liberacion controlada.
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
WO2005058250A2 (en) * 2003-12-17 2005-06-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol for extended sedation
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
MX2009003092A (es) * 2006-09-22 2009-05-08 Labopharm Inc Composiciones y metodos para suministro de farmaco dirigido a ph.
WO2009012303A2 (en) * 2007-07-16 2009-01-22 Northeastern University Therapeutic stable nanoparticles
SI2200588T1 (sl) * 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
FR2930444B1 (fr) * 2008-04-29 2010-06-04 Servier Lab Micelles polymerisees
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof

Also Published As

Publication number Publication date
EP2563349A4 (en) 2014-03-19
US20130039864A1 (en) 2013-02-14
WO2011130834A1 (en) 2011-10-27
IL222568A0 (en) 2012-12-31
IL222568A (en) 2017-05-29
WO2011130834A8 (en) 2013-01-10
EP2563349A1 (en) 2013-03-06
CA2797098A1 (en) 2011-10-27
JP6572256B2 (ja) 2019-09-04
JP2013530931A (ja) 2013-08-01
JP2017186346A (ja) 2017-10-12

Similar Documents

Publication Publication Date Title
JP6572256B2 (ja) 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
RU2523714C2 (ru) Полимерные системы доставки действующих веществ
Hou et al. Phytosomes loaded with mitomycin C–soybean phosphatidylcholine complex developed for drug delivery
CA2805525C (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
Desai Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer
US20190224118A1 (en) Oral gastroretentive formulations and uses thereof
Wang et al. Recent advances in the nanotechnology-based drug delivery of Silybin
KR20200130704A (ko) 약물 전달 시스템
CN103585136A (zh) 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
US20210121414A1 (en) Method for producing a pharmaceutical composition of polymeric nanoparticles for treating neuropathic pain caused by peripheral nerve compression
Pan et al. The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles
NZ759175A (en) Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US9504754B2 (en) Curcuminoid complexes with enhanced stability, solubility and/or bioavailability
Maciejewska‐Stupska et al. Bioavailability enhancement of coenzyme Q10: An update of novel approaches
Alinezhad et al. Utilization of curcumine and nanocurcumine compounds in cancer therapy
Lemasson et al. Are Nanostructured Lipid Carriers (NLC) better than Solid Lipid Nanoparticles (SLN) for delivering abiraterone acetate through the gastrointestinal tract?
CN106913882A (zh) 一种聚乙二醇‑藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用
Nagar et al. Synthesis, characterization and evaluation of retinoic acid-polyethylene glycol nanoassembly as efficient drug delivery system
WO2019094625A1 (en) Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders
CN105012234B (zh) 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途
Ibrahim Nanostructured lipid carriers for oral delivery of a corticosteroid: role of formulation on biopharmaceutical performance
Alavi et al. Green Formulation of Triglyceride/Phospholipid‐Based Nanocarriers as a Novel Vehicle for Oral Coenzyme Q10 Delivery
KR101329573B1 (ko) 인체유래 젤라틴 복합체 및 이의 용도
KR20030071117A (ko) 온도감응성 지질나노입자 조성물과 이를 포함하는 약제조성물
Chakraborty et al. Phospholipid-Based Nanoplatforms: Evolving as Promising Carriers for Therapeutic Intervention

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160405

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317